It’s Here: The 4th Edition of TIF Guidelines for The Management of TDT
TIF, its Board of Directors and its International Scientific Advisory Board proudly present the 4th Edition of the Federation’s most prestigious and renowned publication, the TIF Guidelines for The Management of Transfusion- Dependent Thalassaemia (TDT).
Since 1999, when the very first edition was originally released as part of the Federation’s Educational Programme, the TIF Guidelines have been adopted and used extensively by academics, researchers and healthcare professionals all over the world as the only evidence-based reference text concerning the treatment of patients with TDT.
The newly launched edition includes brand new chapters on the recently approved modalities of patient treatment, the value of patient engagement at the decision-making level, the Reference Centres’ contribution to patient care, and much more.
We are confident that these Guidelines will offer once again valuable information to all allied physicians involved in the treatment of patients with this blood disorder and will consequently benefit the global thalassaemia community many times over.
The June Update: TIF’s Guide on COVID-19 Vaccinations and Therapeutic Drugs
As vaccination rates are slowing in the US and Europe, the spread of the Delta coronavirus variant causes growing concerns worldwide with health experts predicting the highly infectious strain to soon account for the majority of COVID-19 cases globally.
In our latest Guide on ‘COVID-19 Vaccinations and Therapeutic Drugs’, we have gathered the latest news, updates, and the information you need about:
- the current status of COVID-19 vaccinations in major countries and regions
- the clinical development and production of COVID-19 vaccines
- a breakdown of differences between the Pfizer, Moderna, AstraZeneca, and Johnson & Johnson COVID-19 vaccines
- the COVID-19 variants and the existing vaccines’ effectiveness
- the COVID-19 vaccines in Phase 3 clinical trials